Managers / Q1 2020 · view latest →
PARAGON ASSOCIATES & PARAGON ASSOCIATES II JOINT VENTURE
CIK 0001047859 · 500 CRESCENT COURT, SUITE 260, DALLAS, TX, 75201 · 2148713700
Summary
Paragon Associates & Paragon Associates II Joint Venture reported $93M in U.S.-listed holdings across 13 positions for Q1 2020.
The portfolio is heavily concentrated: Reata Pharmaceuticals alone accounts for 31.5% of reported value.
Compared with Q4 2019, the fund opened 3 new positions and exited 9.
Portfolio Metrics
Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded, with multiple share classes and repeated sub-manager rows for the same issuer combined into one position — the same rule the holdings table uses by default. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.
Reported Value by Quarter
Portfolio Composition
- Common Stock · 76.1% · $71M
- ETP · 22.6% · $21M
- Other · 1.3% · $1M
Quarter-over-Quarter Changes full breakdown →
vs Q4 2019 (amended baseline)
| Issuer | Move | Share Δ | Shares now | Value Δ | Value now |
|---|---|---|---|---|---|
| QQQINVESCO QQQ TR | NEW | +60.0K | 60.0K | +$11M | $11M |
| SPYSPDR S&P 500 ETF TR | NEW | +37.5K | 37.5K | +$10M | $10M |
| CFCF INDS HLDGS INC | NEW | +75.0K | 75.0K | +$2M | $2M |
| HUMHUMANA INC | SOLD OUT | −50.0K | 0 | −$18M | $0 |
| OXYOCCIDENTAL PETE CORP | SOLD OUT | −400.0K | 0 | −$16M | $0 |
| ABBVABBVIE INC | SOLD OUT | −150.0K | 0 | −$13M | $0 |
| CICIGNA CORP NEW | SOLD OUT | −50.0K | 0 | −$10M | $0 |
| ELVANTHEM INC | SOLD OUT | −20.0K | 0 | −$6M | $0 |
Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.
Holdings — Q1 2020
| # | Issuer | Class | % Portfolio | Value ↓ | Shares |
|---|---|---|---|---|---|
| 1 | REATA PHARMACEUTICALS INC | CL A | 31.55% | $29M | 203.5K |
| 2 | NEMNEWMONT GOLDCORP CORPORATIONhistory → | COM | 17.02% | $16M | 350.0K |
| 3 | QQQINVESCO QQQ TRhistory → | UNIT SER 1 | 12.27% | $11M | 60.0K |
| 4 | SPYSPDR S&P 500 ETF TRhistory → | TR UNIT | 10.37% | $10M | 37.5K |
| 5 | ABXBARRICK GOLD CORPORATIONhistory → | COM | 9.84% | $9M | 500.0K |
| 6 | NVGSNAVIGATOR HOLDINGS LTDhistory → | SHS | 5.87% | $5M | 1.23M |
| 7 | EPSNEPSILON ENERGY LTDhistory → | COM | 3.11% | $3M | 1.08M |
| 8 | DHXDHI GROUP INChistory → | COM | 2.60% | $2M | 1.12M |
| 9 | IRIXIRIDEX CORPhistory → | COM | 2.25% | $2M | 1.32M |
| 10 | CFCF INDS HLDGS INChistory → | COM | 2.19% | $2M | 75.0K |
| 11 | PARRPAR PACIFIC HOLDINGS INChistory → | COM NEW | 1.53% | $1M | 200.0K |
| 12 | COMMUNITY BANKERS TR CORP | COM | 1.30% | $1M | 250.0K |
| 13 | TUESDAY MORNING CORP | COM NEW | 0.10% | $95,000 | 163.7K |
Filing History
| Quarter | Reported Value | Positions | Filed | Type | Links |
|---|---|---|---|---|---|
| Q1 2026 | $74M | 14 | May 15, 2026 | 13F-HR | changes · EDGAR ↗ |
| Q4 2025 | $48M | 12 | Feb 12, 2026 | 13F-HR | changes · EDGAR ↗ |
| Q3 2025 | $56M | 12 | Nov 12, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q2 2025 | $63M | 15 | Aug 13, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q1 2025 | $43M | 13 | May 13, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q4 2024 | $43M | 12 | Feb 12, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q3 2024 | $56M | 16 | Nov 14, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q2 2024 | $41M | 11 | Aug 13, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q1 2024 | $56M | 16 | May 14, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q4 2023 | $44M | 15 | Feb 14, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q3 2023 | $31M | 10 | Nov 14, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q2 2023 | $49M | 13 | Aug 14, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q1 2023 | $48M | 11 | May 15, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q4 2022 | $54M | 17 | Feb 13, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q3 2022 | $50M | 12 | Nov 14, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q2 2022 | $51M | 11 | Aug 16, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q1 2022 | $54M | 7 | May 16, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q4 2021 | $63M | 10 | Feb 14, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q3 2021 | $88M | 17 | Nov 15, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q2 2021 | $75M | 16 | Aug 16, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q1 2021 | $66M | 11 | May 14, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q4 2020 | $65M | 10 | Feb 12, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q3 2020 | $74M | 8 | Nov 13, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q2 2020 | $91M | 10 | Aug 14, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q1 2020 | $93M | 13 | May 15, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q4 2019 | $178M | 19 | Feb 13, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q3 2019 | $130M | 21 | Nov 13, 2019 | 13F-HR | changes · EDGAR ↗ |
| Q2 2019 | $130M | 25 | Aug 14, 2019 | 13F-HR | changes · EDGAR ↗ |
| Q1 2019 | $106M | 30 | May 14, 2019 | 13F-HR | changes · EDGAR ↗ |
| Q4 2018 | $75M | 21 | Feb 13, 2019 | 13F-HR | changes · EDGAR ↗ |
13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.